share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AWM Investment Company, Inc.(9.2%)

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AWM Investment Company, Inc.(9.2%)

SC 13G/A：超過5%持股股東披露文件(修正)-AWM Investment Company, Inc.(9.2%)
美股SEC公告 ·  11/15 04:35

牛牛AI助理已提取核心訊息

AWM Investment Company, Inc., a Delaware-based investment adviser, has filed an amended Schedule 13G with the SEC, indicating a 9.2% ownership stake in Clene Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reports that AWM holds sole voting and dispositive power over 12,691,213 shares of Clene's common stock. Additionally, AWM has investment power over a significant number of warrants to purchase Clene's common stock, held by various funds under its advisement. The warrants are exercisable provided they do not push AWM's ownership above 10% of Clene's outstanding shares. The principal business address for AWM is listed in New York, NY, and the filing was signed by Adam Stettner, Executive Vice President of AWM, on February 13, 2024.
AWM Investment Company, Inc., a Delaware-based investment adviser, has filed an amended Schedule 13G with the SEC, indicating a 9.2% ownership stake in Clene Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reports that AWM holds sole voting and dispositive power over 12,691,213 shares of Clene's common stock. Additionally, AWM has investment power over a significant number of warrants to purchase Clene's common stock, held by various funds under its advisement. The warrants are exercisable provided they do not push AWM's ownership above 10% of Clene's outstanding shares. The principal business address for AWM is listed in New York, NY, and the filing was signed by Adam Stettner, Executive Vice President of AWM, on February 13, 2024.
AWm投資公司是總部位於特拉華州的投資顧問，已向美國證券交易委員會提交了修訂後的13G表格，顯示其在生物製藥公司Clene Inc.擁有9.2%的所有權。文件日期爲2023年12月31日，報告稱AWm對Clene普通股的12,691,213股享有唯一的表決權和處置權。此外，AWm還對多個由其管理的各類基金持有的購買Clene普通股的大量權證擁有投資權。這些權證可行使，前提是它們不會推動AWm對Clene流通股的持股比例超過10%。AWm的主要業務地址列在紐約，該文件於2024年2月13日由AWm的執行副總裁亞當·斯泰特納簽署。
AWm投資公司是總部位於特拉華州的投資顧問，已向美國證券交易委員會提交了修訂後的13G表格，顯示其在生物製藥公司Clene Inc.擁有9.2%的所有權。文件日期爲2023年12月31日，報告稱AWm對Clene普通股的12,691,213股享有唯一的表決權和處置權。此外，AWm還對多個由其管理的各類基金持有的購買Clene普通股的大量權證擁有投資權。這些權證可行使，前提是它們不會推動AWm對Clene流通股的持股比例超過10%。AWm的主要業務地址列在紐約，該文件於2024年2月13日由AWm的執行副總裁亞當·斯泰特納簽署。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間